ARB Clinical Trials

90 recruitingLast updated: May 13, 2026

There are 90 actively recruiting arb clinical trials across 46 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 4, Early Phase 1, Phase 3. Top locations include Houston, Texas, United States, Shanghai, Shanghai Municipality, China, New York, New York, United States. Updated daily from ClinicalTrials.gov.


ARB Trials at a Glance

90 actively recruiting trials for arb are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Not Applicable with 22 trials, with the heaviest enrollment activity in Houston, Shanghai, and New York. Lead sponsors running arb studies include Bayer, Jian Chen, and Baylor College of Medicine.

Treatments under study

About ARB Clinical Trials

Looking for clinical trials for ARB? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ARB trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ARB clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 90 trials

Recruiting
Phase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer104 enrolled10 locationsNCT06659341
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled746 locationsNCT05334069
Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Bayer150 enrolled76 locationsNCT04142437
Recruiting

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
Bayer100 enrolled1 locationNCT04945330
Recruiting
Phase 1

A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Marburg Virus Disease
International AIDS Vaccine Initiative112 enrolled2 locationsNCT07425821
Recruiting
Phase 1Phase 2

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn+1 more
iECURE, Inc.20 enrolled12 locationsNCT06255782
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Solid TumorsHGGCancer Harboring BRAF Alterations+1 more
Fore Biotherapeutics254 enrolled67 locationsNCT05503797
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

COVID19Influenza vaccinationARB+3 more
Consorci Sanitari de Terrassa3,000 enrolled1 locationNCT04367883
Recruiting
Phase 1Phase 2

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

ARBBVMDAutosomal-Dominant Bestrophinopathy+1 more
Opus Genetics, Inc10 enrolled4 locationsNCT07185256
Recruiting

Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children

Carbapenem-Resistant Enterobacteriaceae Infection
Children's Hospital of Fudan University536 enrolled1 locationNCT04535661
Recruiting
Phase 4

Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB

Ceftazidime-avibactamAztreonamGram-negative Bacterial Infection+2 more
Jing Zhou144 enrolled1 locationNCT07478484
Recruiting
Phase 1

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.96 enrolled5 locationsNCT06716138
Recruiting
Phase 2

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more
University of Washington20 enrolled1 locationNCT06442475
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Solid Tumors Harboring MET Amplification
AbbVie125 enrolled26 locationsNCT07196644
Recruiting
Phase 1

A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.120 enrolled1 locationNCT07189949
Recruiting

ARBOspot: Characterization of Arbovirus Specific T Cell Response in Patients by Using Enzyme Linked Immunospot (ELISpot) Assays

Arbovirus Infections
Fondazione IRCCS Policlinico San Matteo di Pavia500 enrolled1 locationNCT07291206
Recruiting
Phase 2

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma+1 more
M.D. Anderson Cancer Center31 enrolled1 locationNCT04745949
Recruiting
Not Applicable

Comparison of Wound Healing for Diabetic Carbuncle Treated With Incision and Drainage Technique Using Cruciate Incision vs Saucerization Technique Both Followed by Vacuum Assisted Closure.

Carbuncle
King Edward Medical University124 enrolled1 locationNCT07428265
Recruiting
Phase 1Phase 2

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.

Healthy ParticipantsSarbecovirus
SK Bioscience Co., Ltd.368 enrolled2 locationsNCT07280858